Author: SciNeuro Pharmaceuticals

SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer’s Disease

January 12, 2026
SciNeuro Pharmaceuticals Announces $53 Million Financing to Further Advance Pipeline of Therapies for Neurodegenerative Diseases and Appointment of Chief Financial Officer

December 5, 2025

SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer’s Disease